Professor Sir Rory Collins
Research groups
- ATLAS: International ATLAS (Adjuvant Tamoxifen Longer Against Shorter) Breast Cancer Treatment Trial
- ATT: Antithrombotic Trialists' Collaboration
- CTT: Cholesterol Treatment Trialists' Collaboration
- HPS3 / TIMI 55 - REVEAL : Randomised Evaluation of the Effects of Anacetrapib through Lipid-modification
- HPS: Heart Protection Study
- International Study of Infarct Survival (ISIS)
- Mexico City Prospective Study
- Oxford Cholesterol Study
- PSC
- Research Regulation
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
- The Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
- Trials Methodology
- UK Biobank
Colleges
Websites
-
UK Biobank
Principal Investigator and Chief Execuitve
-
British Heart Foundation
Professor of Medicine and Epidemiology
-
Tokai University
Adjunctive Professor
-
China Oxford Centre for International Health Research
Honorary Director
-
Beijing Union Medical College and Chinese Academy of Medical Sciences
Honorary Professor
Rory Collins
FRS, FMedSci
Head of Nuffield Department of Population Health and BHF Professor of Medicine and Epidemiology
Rory Collins studied Medicine at St Thomas’s Hospital Medical School, London University (1974-1980), and Statistics at George Washington University (1976-7) and at Oxford University (1982-3).
In 1985 he became co-director, with Professor Sir Richard Peto, of the University of Oxford's Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). In 1996, he was appointed Professor of Medicine and Epidemiology at Oxford, supported by the British Heart Foundation.
He became Principal Investigator and Chief Executive of the UK Biobank prospective study of 500,000 people in September 2005. From July 2013, he became the Head of the Nuffield Department of Population Health at Oxford University.
His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer. He was knighted in 2011 for his services to science.
Key publications
-
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Journal article
Baigent C. et al, (2005), Lancet, 366, 1267 - 1278
-
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Journal article
Antithrombotic Trialists' Collaboration None., (2002), BMJ, 324, 71 - 86
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Journal article
Heart Protection Study Collaborative Group None., (2002), Lancet, 360, 7 - 22
Recent publications
-
Association between health insurance cost-sharing and choice of hospital tier for cardiovascular diseases in China: a prospective cohort study.
Journal article
Levy M. et al, (2024), Lancet Reg Health West Pac, 45
-
Causal association between snoring and stroke: a Mendelian randomization study in a Chinese population.
Journal article
Zhu Y. et al, (2024), Lancet Reg Health West Pac, 44
-
Author Correction: Genotyping, sequencing and analysis of 140,000 adults from Mexico City.
Journal article
Ziyatdinov A. et al, (2024), Nature, 626
-
PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations
Journal article
CHEN Z. et al, (2024), European Journal of Preventive Cardiology
-
Prospective study design and data analysis in UK Biobank.
Journal article
Allen NE. et al, (2024), Science translational medicine, 16